|Slideshows|December 2, 2019

Year in Review: 2019 Special Reports in Psychiatry

Author(s)Heidi Anne Duerr, MPH, Laurie Martin

As varied as the field of psychiatry itself, our Special Report collections covered issues such as eating disorders, traumatic brain injury, practice management, schizophrenia and depression, complex medical comorbidities, and more. Here's a sampling.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Metabolic Risk, Residual Insomnia, and Seltorexant

ByJane Tiller, MD

June 25th 2026

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

Seltorexant as Adjunctive Therapy for MDD With Insomnia

ByJane Tiller, MD

June 24th 2026

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

ByLeah Kuntz

June 22nd 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Year in Review: 2019 Special Reports in Psychiatry

Related Content

Metabolic Risk, Residual Insomnia, and Seltorexant

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Seltorexant as Adjunctive Therapy for MDD With Insomnia